Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Executive Summary

Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.

Advertisement

Related Content

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
Gilead Lowering HCV Drug List Prices With Authorized Generics
Harper, Hooper Exit As Amgen Revenues Rise
Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives
Trump Tries To Shame A Defiant Pfizer On Drug Pricing
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel